Results 31 to 40 of about 2,911,119 (244)

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients

Current Oncology, 2021
Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman, Stephen Yip   +10 more
doaj   +1 more source

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Current Oncology, 2021
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao   +17 more
doaj   +1 more source

Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models [PDF]

Br J Clin Pharmacol, 2018
P. Loudon, P. Siebenga, Donal N. Gorman, K. Gore, P. Dua, Guido van Amerongen, J. Hay, G. Groeneveld, R. Butt   +8 more
semanticscholar   +2 more sources

TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer [PDF]

Journal of Cancer, 2021
Tropomyosin receptor kinase (TRK) fusion is one of the oncogenic driver causes of colon cancer, and tropomyosin 3-neurotrophic receptor tyrosine kinase 1 (TPM3-NTRK1) fusion has been detected in the KM12SM cell line. In the present study, we investigated anticancer mechanisms in the KM12SM cell line using three different form of dovitinib (dovitinib ...
Sohn, Sung-Hwa, Sul, Hee Jung, Kim, Bohyun, Kim, Bum Jun, Kim, Hyeong Su, Zang, Dae Young   +5 more
openaire   +2 more sources

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma

Frontiers in Oncology, 2023
NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display ...
Qing-Xiang Yu, Wen-Jun Zhao, He-Yue Wang, Lei Zhang, Lan Qin, Lei Zhang, Jian-li Han   +6 more
doaj   +1 more source

Precision oncology: the intention-to-treat analysis fallacy. [PDF]

, 2020
It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
Kato, Shumei, Kurzrock, Razelle, Okamura, Ryosuke, Sicklick, Jason K   +3 more
core   +1 more source

Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal NTRK1 Fusion: Case Report

JTO Clinical and Research Reports, 2023
The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC.
Mary C. Boulanger, MD, Jennifer S. Temel, MD, Mari Mino-Kenudson, MD, Lauren L. Ritterhouse, MD, PhD, Ibiayi Dagogo-Jack, MD   +4 more
doaj   +1 more source

NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern

Human Pathology Reports, 2022
Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers found in a few rare tumours. However, NTRK rearrangements are being increasingly identified in a range of soft tissue neoplasms. Recognition of NTRK fusion-driven sarcomas is
Vanessa Young, Daniel Wong, Max Yan, Fiona Maclean   +3 more
doaj   +1 more source

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

Thoracic Cancer, 2022
Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application.
Chunwei Xu, Lu Si, Wenxian Wang, Ziming Li, Zhengbo Song, Qian Wang, Aijun Liu, Jinpu Yu, Wenfeng Fang, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Xingxiang Pu, Rongbo Lin, Weifeng Liu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Lei Lei, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Junli Xue, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Xiao Hu, Jin Zhou, Zhengfei Zhu, Yongheng Li, Hong Qiu, Fan Xia, Yuanyuan Lu, Xiaofeng Chen, Rui Ge, Enyong Dai, Yu Han, Weiwei Pan, Jiancheng Luo, Hongtao Jia, Xiaowei Dong, Fei Pang, Kai Wang, Liping Wang, Youcai Zhu, Yanru Xie, Xinqin Lin, Jing Cai, Jia Wei, Fen Lan, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Bing Wan, Donglai Lv, Qing Wei, Jin Kang, Jiatao Zhang, Chao Zhang, Genhua Yu, Juanjuan Ou, Lin Shi, Zhongwu Li, Zhefeng Liu, Jing Liu, Nong Yang, Lin Wu, Huijuan Wang, Gu Jin, Liu Yang, Guansong Wang, Meiyu Fang, Yong Fang, Yuan Li, Xiaojia Wang, Yiping Zhang, Shenglin Ma, Biyun Wang, Xiaotian Zhang, Yong Song, Yuanzhi Lu   +110 more
doaj   +1 more source

EXTH-80. PBI-200: IN VIVO EFFICACY OF A NOVEL, HIGHLY CNS-PENETRANT NEXT GENERATION TRK INHIBITOR

Neuro-Oncology, 2021
TRK kinases (TRK) are clinically validated targets for cancers harboring NTRK gene fusions. However, approved TRK inhibitors (TRKi) give rise to mutations reducing long-term clinical efficacy, and display limited CNS penetration that may impact their ...
K. Pal, A. Régina, A. Elagoz, V. Albert, Johnathan Boudreault, M. Ouellet, L. Pilote, Nicolas Bruneau-Latour, Hong Wang, L. Tao, É. Bellavance, P. White, Stephane Ciblat, J.-F. Leef, R. Bishop   +14 more
semanticscholar   +1 more source